Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 in healthy volunteers
NCT03594890Phase 1Completed
- Sponsor
- Osivax
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of OVX836 in influenza (4 arms), sponsored by Osivax. Primary endpoints: Out-of-Range Safety Lab data, Solicited local and systemic reactions and 2 more. Started Jun 2018; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03594890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594890.